Opinion on  Illumina Inc (ILMN)     Sector: Technology  >  Industry: Scientific & Technical Instr.
Illumina Inc

Analysts'  Recommendation:	Strong Buy
30 Days Ago:	Strong Buy
Analysts' Target:	$100

Analysts' Targets
UBS Securities	$110
Neutral
Tuesday, July 08, 2008
Caris & Company	$97
Average
Wednesday, July 02, 2008
Deutsche Bank Securities	$108
Hold
Wednesday, April 23, 2008
Lehman Brothers	$85
Equal-weight
Wednesday, April 23, 2008

llumina, Inc. engages in the development, manufacture, and marketing of integrated systems for the analysis of genetic variation and biological function. It provides a line of products and services that serve the sequencing, genotyping, and gene expression markets. The company’s single-nucleotide polymorphism (SNP) genotyping product consists of Array Matrix, which uses a universal format that allows it to analyze various sets of SNPs, as well as offers Human 1M DNA Analysis BeadChip that combines an unprecedented level of content for both whole-genome and CNV analysis; HumanCNV370-Duo BeadChip, which enables researchers to analyze two samples simultaneously and access novel content for detecting disease-relevant CNV regions; and HumanHap550-Duo BeadChip. The company also provides BeadStation, a system for performing genotyping, which comprises BeadArray Reader, a scanning instrument that uses a laser to read the results of experiments that are captured in its instruments and genotyping and/or gene expression analysis software; and oligos, which are components of the reagent kits for its BeadArray products and are used for assay development. In addition, the company develops and commercializes genetic analysis technologies used for various analyses, including whole genome resequencing, gene expression analysis, and RNA analysis. It has collaborations with Invitrogen Corporation for the manufacture, marketing, and distribution of oligos; and deCODE genetics, ehf. to develop and commercialize diagnostic tests for variants in genes involved in disease related pathways linked to heart attack, type 2 diabetes, and breast cancer. The company was founded in 1998 and is headquartered in San Diego, California.
www.illumina.com